admin

With this fourth chapter, we complete our journey through 150 years of thalassemia history by entering the most recent—and perhaps most transformative—period: the era of advanced therapies aimed at cure. After decades marked by progress in transfusion therapy, iron chelation, and the first cellular strategies, research has now opened scenarios…

Honoring Sebastiano D’Agostino Legacy: Award Ceremony on January 16, 2026 The D’Agostino Prize 2025, established in honor of D’Agostino’s enduring legacy and lifelong commitment to healthcare, will be awarded on January 16, 2026. This Prize celebrates scientific excellence and innovation in a field where research continues to make a profound…

The Role of Collaboration between Regulatory Agencies and Researchers in Promoting Innovation for Hematological Rare Diseases As part of the 2025–2026 GARDEN Educational Series, the Global Hematological Rare Diseases Alliance (GARDEN) and the Franco and Piera Cutino Foundation are pleased to announce the upcoming CME webinar dedicated to innovation and…

Sebastiano D’Agostino (1933-2024)Vision, Innovation and Public Service in Healthcare Sebastiano D’Agostino’s professional life embodies a deep commitment to public healthcare, spanning over four decades of service in Sicily during a time of profound transformation. His career intersected with significant milestones in Italian healthcare history, from the 1950s and 1960s, marked…

In this third stage of our historical journey, we explore the period when oral chelation therapies became available, offering patients a more practical and less invasive alternative to subcutaneous treatment. This era also marks the beginning of innovative cellular approaches to thalassemia therapy, laying the groundwork for future advances toward…

In a rare show of unity, San Rocco Therapeutics is being praised across the political spectrum for its mission to deliver a safe and accessible gene therapy for sickle cell disease. With backing from both Republican and Democratic leaders, the company stands out for challenging high-cost pharma models and putting…

As part of a broader training program scheduled throughout 2025 and 2026, GARDEN Network and the Franco and Piera Cutino Foundation are pleased to announce the return of the Garden Educational Events, starting in September 2025. This initiative offers a valuable opportunity for healthcare professionals involved in the management of…

In this brief journey through history, we will provide insights—and in some cases, interesting facts—about the key figures and discoveries that have progressively led to a radical shift in the approach to treating thalassemia patients over the past 150 years. This story is divided into four chapters: Chapter 1: The…

Watch the Soft White Underbelly interview and portrait of Patrick Girondi — an Italian-American singer-songwriter, author, and founder of San Rocco Therapeutics, a gene therapy company committed to developing safe and accessible cures for Sickle Cell Disease and Thalassemia. Originally from the South Side of Chicago, Girondi has released seven…

As part of the GARDEN Network’s continuous effort to share valuable resources in the field of rare hematological diseases, this month we feature the work of Prof. Carlo Dufour on the modern management of Fanconi anemia. This rare genetic disorder, characterized by progressive bone marrow failure and cancer predisposition, remains…